Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction

• Verfasst von: Hoffmann, Jochen [VerfasserIn]
• Verfasst von: Hartmann, Martin [VerfasserIn]
• Verfasst von: Enk, Alexander [VerfasserIn]
• Verfasst von: Hadaschik, Eva [VerfasserIn]
• Titel: Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction
• Verf.angabe: J.H.O. Hoffmann, M. Hartmann, A.H. Enk and E.N. Hadaschik
• E-Jahr: 2011
• Jahr: 01 August 2011
• Umfang: 4 S.
• Illustrationen: Diagramme
• Fussnoten: Gesehen am 29.07.2022
• Titel Quelle: Enthalten in: British journal of dermatology
• Ort Quelle: Oxford : Wiley-Blackwell, 1892
• Jahr Quelle: 2011
• Band/Heft Quelle: 165(2011), 6, Seite 1355-1358
• ISSN Quelle: 1365-2133
• DOI: doi:10.1111/j.1365-2133.2011.10555.x
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1811999875

Abstract

Background Infliximab is successfully used to treat psoriasis and psoriatic arthritis. However, some patients lose therapeutic response after several cycles. Antibodies to infliximab (infliximab-Abs) are induced during treatment in a subgroup of patients and are thought to be associated with loss of response (LOR). Routine screening for infliximab-Abs is expensive and not regularly performed. A reliable and affordable method for identifying patients who are at risk for LOR to infliximab is desirable. Objectives To analyse the development of antinuclear antibodies (ANA)/antidouble-stranded DNA antibodies (anti-dsDNA) over time in patients with psoriasis receiving infliximab. To analyse if there is an association between ANA titres/anti-dsDNA concentrations, infliximab-Ab status and LOR. Methods A retrospective data analysis of 29 patients with psoriasis receiving infliximab was carried out. ANA titres and anti-dsDNA concentrations were regularly monitored in these patients and sera were tested for infliximab-Abs by enzyme-linked immunosorbent assay. Results Median ANA titres increased from 1 : 80 [interquartile range (IQR) 0 to 1 : 320, n = 29] pretreatment, to 1 : 1280 (IQR 1 : 640 to 1 : 1920, n = 15) after infusion 10, and 1 : 1920 (IQR 1 : 1280 to 1 : 2560, n = 10) after infusion 20. Infliximab-Abs were found in 21% of patients. Infliximab-Ab-positive patients and patients with LOR had significantly higher pretreatment anti-dsDNA concentrations and higher pretreatment ANA titres than infliximab-Ab-negative and responsive patients, respectively. Conclusions The results of this study suggest a role for autoantibodies in the identification of patients with psoriasis at higher risk of developing infliximab-Abs and of LOR under treatment with infliximab.